Resmed Inc (RMD): who owns it and who trades it
As of Nov 16, 2026, RMD insiders reported 29 open-market sales worth $20.2M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Michael J. Farrell (CEO), with $13.8M. 6 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Resmed
From the latest filingsOverall: about as much buying as selling. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns RMD
881 funds and institutions reported RMD shares worth $19.7B at the end of Q2 2026, about 70% of the company. The largest holder is BlackRock, Inc. with 8.5%.
Funds and institutions (13F) 70%Everyone else 30%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 12.32M | 8.49% | $2.4B | +2% |
| Vanguard Capital Management LLC | 9.47M | 6.53% | $1.8B | +0% |
| Vanguard Portfolio Management LLC | 7.91M | 5.46% | $1.5B | +1% |
| State Street Corp | 6.68M | 4.61% | $1.3B | +1% |
| Geode Capital Management, LLC | 4.35M | 3.00% | $845M | No change |
| Bank of New York Mellon Corp | 4.20M | 2.89% | $818M | -15% |
| First Trust Advisors LP | 2.28M | 1.57% | $444M | +48% |
| Invesco Ltd. | 2.06M | 1.42% | $402M | +5% |
| Morgan Stanley | 1.93M | 1.33% | $376M | -28% |
| Northern Trust Corp | 1.70M | 1.17% | $331M | -2% |
| Nordea Investment Management AB | 1.39M | 0.96% | $270M | +34% |
| Deutsche Bank Ag\ | 1.32M | 0.91% | $258M | -7% |
| UBS Group AG | 1.29M | 0.89% | $251M | +77% |
| Swedbank AB | 1.27M | 0.88% | $248M | -6% |
| Charles Schwab Investment Management Inc | 1.22M | 0.84% | $238M | +8% |
| Sixth Street Partners Management Company, L.P. | 1.22M | 0.84% | $238M | – |
| Goldman Sachs Group Inc | 1.16M | 0.80% | $226M | +16% |
| Arrowstreet Capital, Limited Partnership | 1.13M | 0.78% | $220M | +151% |
| Dimensional Fund Advisors LP | 1.12M | 0.77% | $219M | +12% |
| Legal & General Group Plc | 942,614 | 0.65% | $184M | -5% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, RMD insiders reported $0 of open-market purchases and $20.2M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 9, 2026 | Michael J. Farrell | CEO | Sale plan | 4,993 | $235.35 | $1.2M | Form 4 |
| Oct 23, 2026 | Michael J Rider | Global General Counsel | Sale plan | 400 | $255.00 | $102K | Form 4 |
| Oct 7, 2026 | Michael J. Farrell | CEO | Sale plan | 4,991 | $226.33 | $1.1M | Form 4 |
| Sep 8, 2026 | Michael J. Farrell | CEO | Sale plan | 4,991 | $222.44 | $1.1M | Form 4 |
| Sep 2, 2026 | Peter C Farrell | Director | Sale plan | 970 | $234.73 | $228K | Form 4 |
| Aug 7, 2026 | Michael J. Farrell | CEO | Sale plan | 4,991 | $205.69 | $1M | Form 4 |
| Aug 5, 2026 | Peter C Farrell | Director | Sale plan | 8,000 | $225.00 | $1.8M | Form 4 |
| Jul 7, 2026 | Michael J. Farrell | CEO | Sale plan | 4,991 | $218.55 | $1.1M | Form 4 |
| Jun 8, 2026 | Michael J. Farrell | CEO | Sale plan | 4,991 | $193.96 | $968K | Form 4 |
| May 7, 2026 | Michael J. Farrell | CEO | Sale plan | 4,991 | $207.82 | $1M | Form 4 |
| Apr 7, 2026 | Michael J. Farrell | CEO | Sale plan | 4,991 | $225.50 | $1.1M | Form 4 |
| Apr 1, 2026 | Brett Sandercock | CFO | Sale plan | 1,000 | $224.31 | $224K | Form 4 |
| Apr 1, 2026 | Peter C Farrell | Director | Sale plan | 2,000 | $225.00 | $450K | Form 4 |
| Mar 9, 2026 | Michael J. Farrell | CEO | Sale plan | 4,991 | $251.03 | $1.3M | Form 4 |
| Mar 4, 2026 | Peter C Farrell | Director | Sale plan | 2,000 | $260.22 | $520K | Form 4 |
| Mar 2, 2026 | Brett Sandercock | CFO | Sale plan | 1,000 | $254.30 | $254K | Form 4 |
| Feb 9, 2026 | Michael J. Farrell | CEO | Sale plan | 4,991 | $273.78 | $1.4M | Form 4 |
| Feb 4, 2026 | Peter C Farrell | Director | Sale plan | 2,000 | $251.31 | $503K | Form 4 |
| Feb 4, 2026 | Michael J Rider | Global General Counsel | Sale plan | 50 | $260.00 | $13K | Form 4 |
| Feb 2, 2026 | Brett Sandercock | CFO | Sale plan | 1,000 | $257.03 | $257K | Form 4 |
| Jan 7, 2026 | Peter C Farrell | Director | Sale plan | 2,000 | $248.83 | $498K | Form 4 |
| Jan 7, 2026 | Michael J. Farrell | CEO | Sale plan | 4,991 | $248.46 | $1.2M | Form 4 |
| Jan 2, 2026 | Brett Sandercock | CFO | Sale plan | 1,000 | $241.75 | $242K | Form 4 |
| Jan 2, 2026 | Michael J Rider | Global General Counsel | Sale plan | 50 | $241.75 | $12.1K | Form 4 |
| Dec 8, 2025 | Michael J. Farrell | CEO | Sale plan | 4,991 | $251.41 | $1.3M | Form 4 |
| Dec 3, 2025 | Peter C Farrell | Director | Sale plan | 2,000 | $251.47 | $503K | Form 4 |
| Dec 1, 2025 | Michael J Rider | Global General Counsel | Sale plan | 50 | $244.16 | $12.2K | Form 4 |
| Dec 1, 2025 | Brett Sandercock | CFO | Sale plan | 1,000 | $244.16 | $244K | Form 4 |
| Nov 25, 2025 | Witte Jan De | Director | Sale plan | 2,055 | $255.00 | $524K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Michael J. Farrell | Chairman and CEO, Director | – | $13.8M | Nov 9, 2026 |
| Peter C Farrell | Director | – | $4.5M | Sep 2, 2026 |
| Brett Sandercock | Chief Financial Officer | – | $1.2M | Apr 1, 2026 |
| Witte Jan De | Director | – | $524K | Nov 25, 2025 |
| Michael J Rider | Global General Counsel | – | $139K | Oct 23, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
RMD short interest
Moderate short interest. 7.4% of RMD shares are sold short: about 1 share in 13. Over the last 12 reports the number of shares short went down 23%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 10.47M RMD shares were sold short, 7.4% of the shares outstanding, down 12.2% from the report before. At the average daily volume of 1.49M shares, buying them all back would take about 7.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 10.47M | 7.44% | -12% | 1.49M | 7.0 |
| Oct 15, 2026 | 11.92M | 8.26% | -7% | 966,537 | 12.3 |
| Sep 30, 2026 | 12.78M | 8.86% | -10% | 1.29M | 9.9 |
| Sep 15, 2026 | 14.20M | 9.85% | +9% | 1.21M | 11.7 |
| Aug 31, 2026 | 13.07M | 9.06% | +2% | 1.46M | 8.9 |
| Aug 14, 2026 | 12.79M | 8.87% | -18% | 1.73M | 7.4 |
| Jul 31, 2026 | 15.68M | 10.81% | +16% | 1.10M | 14.2 |
| Jul 15, 2026 | 13.54M | 9.34% | -10% | 1.73M | 7.8 |
| Jun 30, 2026 | 15.10M | 10.41% | +17% | 1.78M | 8.5 |
| Jun 15, 2026 | 12.92M | 8.90% | +9% | 1.43M | 9.0 |
| May 29, 2026 | 11.88M | 8.19% | -12% | 1.62M | 7.3 |
| May 15, 2026 | 13.57M | 9.36% | +10% | 1.61M | 8.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded RMD
Since Nov 17, 2024, 3 members of Congress reported 1 purchase and 3 sales of RMD. The latest was a purchase by Alan Armstrong on Mar 27, 2026, reported Jul 21, 2026.
Purchases 1Sales 3
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Mar 27, 2026 | Alan Armstrong (R-OK) | Purchase | $1K–$15K | Self | Jul 21, 2026 | Report |
| Jun 4, 2025 | Kelly Morrison (D-MN) | Sale | $1K–$15K | Self | Jun 18, 2025 | Report |
| Apr 28, 2025 | Kelly Morrison (D-MN) | Sale | $1K–$15K | Self | May 13, 2025 | Report |
| Jan 13, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Sale | $1K–$15K | Joint | Feb 13, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Resmed company events
Resmed filed 9 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, auditor). The latest was on Oct 29, 2026.
- Oct 29, 2026AnnouncementWe announced that our board of directors declared a quarterly cash dividend of US $0.66 per share. Filing
- Sep 1, 2026AnnouncementResMed Inc. entered into an accelerated share repurchase agreement with Citibank, N.A. to repurchase $450.0 million of the Company’s shares of common stock, par value $0.004 per share. Filing
- Aug 17, 2026AuditorChanges in the Registrant’s Certifying Accountant. Filing
- Aug 6, 2026AnnouncementWe announced that our board of directors declared a quarterly cash dividend of US $0.66 per share, representing an increase of 10% over the previous quarterly dividend. Filing
- Jul 7, 2026ResultsReleased financial results. Filing
- Apr 30, 2026LeadershipResMed Inc. announced that Brett Sandercock, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, will retire from his role as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer. Filing
- Apr 30, 2026AnnouncementWe announced that our board of directors declared a quarterly cash dividend of US $0.60 per share. Filing
- Jan 29, 2026AnnouncementWe announced that our board of directors declared a quarterly cash dividend of US $0.60 per share. Filing
- Nov 20, 2025LeadershipRichard Sulpizio did not seek re-election at the Annual Meeting (as defined below); his term expired on November 19, 2025 at the conclusion of the Annual Meeting, creating a vacancy on our board of directors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Resmed financials
Famous investors that hold RMD
6 of the 50 well-known investors we track reported holding RMD in their latest 13F filing. The largest position is Ken Griffin's, worth $117M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 527,861 | $117M | 0.1% | +4% |
| Israel Englander · Millennium Management | Q3 2026 | 100,045 | $22.1M | 0.0% | -51% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 93,920 | $20.8M | 0.0% | +5698% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 63,175 | $14M | 0.0% | +20% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 14,487 | $3.2M | 0.0% | -78% |
| Jeremy Grantham · GMO | Q3 2026 | 5,721 | $1.3M | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Resmed Inc (RMD) stock
Who owns the most RMD stock?
The largest reported owner of Resmed Inc (RMD) is BlackRock, Inc., with 8.5% of the company. In total, 881 funds and institutions reported holding RMD at the end of Q2 2026, together about 70% of the shares. See the largest owners.
Are RMD insiders buying or selling?
In the last 12 months, RMD insiders reported no open-market purchases and 29 sales worth $20.2M. The latest trade was on Nov 9, 2026. See every trade.
What is the short interest in RMD?
As of Oct 30, 2026, 10.47M RMD shares were sold short, 7.4% of the shares outstanding, down 12.2% from the report before. At the average daily volume of 1.49M shares, buying them all back would take about 7.0 trading days (days to cover). See the history.
Have members of Congress traded RMD?
Yes. 3 members of Congress reported 1 purchase and 3 sales of RMD since Nov 17, 2024. The latest was reported on Jul 21, 2026. See the trades.
Which famous investors hold RMD?
6 of the 50 well-known investors we track reported RMD in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $117M. See all holders.
Executive pay
Resmed's chief executive was paid a total of $16.2M for the year ended Jun 30, 2026, up 10% from $14.7M the year before. In the last 12 months, Resmed's executives and directors bought no stock on the open market and sold $20.2M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.